Eisai : RECEIVES APPROVAL TO MARKET INSOMNIA TREATMENT LUNESTA® IN JAPAN
January 18, 2012 at 07:31 am
By
Share
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO:
Haruo Naito, "Eisai") announced today that it received
approval from Japan's Ministry of Health, Labour and
Welfare (MHLW) on January 18, 2012 to market Lunesta®
(eszopiclone), a product the company has been developing in
Japan, as a treatment for insomnia.
Lunesta, originally discovered and developed by Sunovion
Pharmaceuticals Inc. ("Sunovion"; formerly Sepracor Inc.,
"Sepracor"; a U.S. subsidiary of Dainippon Sumitomo Pharma
Co., Ltd.), has been marketed in the United States since
April 2005. The agent was approved as the first insomnia
treatment not to have restrictions on its length of use,
and is widely used by individuals suffering from insomnia.
Eisai has been pursuing the development of Lunesta since
acquiring the exclusive rights to develop and market it in
Japan from Sunovion (at the time known as Sepracor) in July
2007. The company submitted a marketing authorization
application to the MHLW in November 2010.
Lunesta is a non-benzodiazepine type GABAA agonist that is
believed to enhance GABA activity while exerting hypnotic
and sedative effects. Results from clinical studies
conducted in Japan and overseas demonstrated that the agent
is effective in those patients who have trouble falling
asleep or wake up often during the night, two major
symptoms of insomnia. A distinctive feature of Lunesta is
that patients do not experience clinically problematic
issues such as dependency or carry-over effects or develop
a tolerance (experience diminished efficacy) with long-term
use.
In a Phase II/III study (Study 126) conducted in Japan in
patients with primary insomnia, Lunesta was shown to
statistically significantly improve Sleep Latency (SL)1) as
measured against placebo. In addition, Lunesta was shown in
Study 126 to cause a statistically significant (when
measured against placebo) reduction in latency to
persistent sleep (LPS), as objectively measured by an
overnight polysomnography (PSG)2). The measurement of the
impact of Lunesta on SL and LPS were the two co-primary
endpoints of Study 126. The favorable safety profile of
Lunesta was also confirmed in a long-term study (Study 150)
in patients with various forms of insomnia, including
elderly adults and adults with insomnia associated with
psychological disorders.
Insomnia is a condition that has a repeated negative effect
on a person's ability to fall asleep, remain asleep or
obtain quality of sleep, and can interfere with everyday
activities despite having ample opportunity to sleep. In
Japan, it is estimated that more than 20 million people
suffer
Eisai Company specializes in the manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical products (87.7%): prescribed drugs, health products, etc.;
- other (12.3%): food additives, chemical products, etc.
Net sales are distributed geographically as follows: Japan (46.2%), Europe (19.5%), Americas (15.5%), China (10.3%) and other (8.4%).